Literature DB >> 20556744

Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.

Sandra D Castillo1, Barbara Angulo, Ana Suarez-Gauthier, Lorenzo Melchor, Pedro P Medina, Lydia Sanchez-Verde, Juan Torres-Lanzas, Guillermo Pita, Javier Benitez, Montse Sanchez-Cespedes.   

Abstract

The search for novel oncogenes is important because they could be the target of future specific anticancer therapies. In the present paper we report the identification of novel amplified genes in lung cancer by means of global gene expression analysis. To screen for amplicons, we aligned the gene expression data according to the position of transcripts in the human genome and searched for clusters of over-expressed genes. We found several clusters with gene over-expression, suggesting an underlying genomic amplification. FISH and microarray analysis for DNA copy number in two clusters, at chromosomes 11q12 and 13q34, confirmed the presence of amplifications spanning about 0.4 and 1 Mb for 11q12 and 13q34, respectively. Amplification at these regions each occurred at a frequency of 3%. Moreover, quantitative RT-PCR of each individual transcript within the amplicons allowed us to verify the increased in gene expression of several genes. The p120ctn and DP1 proteins, encoded by two candidate oncogenes, CTNND1 and TFDP1, at 11q12 and 13q amplicons, respectively, showed very strong immunostaining in lung tumours with gene amplification. We then focused on the 13q34 amplicon and in the TFDP1 candidate oncogene. To further determine the oncogenic properties of DP1, we searched for lung cancer cell lines carrying TFDP1 amplification. Depletion of TFDP1 expression by small interference RNA in a lung cancer cell line (HCC33) with TFDP1 amplification and protein over-expression reduced cell viability by 50%. In conclusion, we report the identification of two novel amplicons, at 13q34 and 11q12, each occurring at a frequency of 3% of non-small cell lung cancers. TFDP1, which encodes the E2F-associated transcription factor DP1 is a candidate oncogene at 13q34. The data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series Accession No. GSE21168.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556744     DOI: 10.1002/path.2732

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  18 in total

1.  PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.

Authors:  Ester Bonastre; Sara Verdura; Ilse Zondervan; Federica Facchinetti; Sylvie Lantuejoul; Maria Dolores Chiara; Juan Pablo Rodrigo; Julian Carretero; Enric Condom; Agustin Vidal; David Sidransky; Alberto Villanueva; Luca Roz; Elisabeth Brambilla; Suvi Savola; Montse Sanchez-Cespedes
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

2.  Next-generation sequencing of colorectal cancers in chinese: identification of a recurrent frame-shift and gain-of-function Indel mutation in the TFDP1 gene.

Authors:  Chen Chen; Jie Liu; Fan Zhou; Jianbo Sun; Lisha Li; Chengmeng Jin; Jiaofang Shao; Huawei Jiang; Na Zhao; Shu Zheng; Biaoyang Lin
Journal:  OMICS       Date:  2014-08-18

3.  Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5.

Authors:  Hui Tian; Jui-Yun Lu; Chunli Shao; Kenneth E Huffman; Ryan M Carstens; Jill E Larsen; Luc Girard; Hui Liu; Jaime Rodriguez-Canales; Eugene P Frenkel; Ignacio I Wistuba; John D Minna; Sandra L Hofmann
Journal:  Mol Cancer Res       Date:  2015-01-08       Impact factor: 5.852

4.  δ-Catenin dysregulation in cancer: interactions with E-cadherin and beyond.

Authors:  Qun Lu
Journal:  J Pathol       Date:  2010-10       Impact factor: 7.996

5.  MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.

Authors:  Paula Llabata; Manuel Torres-Diz; Antonio Gomez; Laureano Tomas-Daza; Octavio A Romero; Joaquim Grego-Bessa; Pere Llinas-Arias; Alfonso Valencia; Manel Esteller; Biola M Javierre; Xiaoyang Zhang; Montse Sanchez-Cespedes
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

6.  Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma.

Authors:  Guiyuan Li; Shengming Yi; Fan Yang; Yongxin Zhou; Qiang Ji; Jianzhi Cai; Yunqing Mei
Journal:  Thorac Cancer       Date:  2014-04-22       Impact factor: 3.500

7.  CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression.

Authors:  Yunshan Wang; Mingxin Wen; Yongwon Kwon; Yangyang Xu; Yueyong Liu; Pengju Zhang; Xiuquan He; Qin Wang; Yurong Huang; Kuang-Yu Jen; Mark A LaBarge; Liang You; Scott C Kogan; Joe W Gray; Jian-Hua Mao; Guangwei Wei
Journal:  Cancer Res       Date:  2013-12-04       Impact factor: 12.701

8.  Lung tumourigenesis in a conditional Cul4A transgenic mouse model.

Authors:  Yi-Lin Yang; Ming-Szu Hung; Yang Wang; Jian Ni; Jian-Hua Mao; David Hsieh; Alfred Au; Atul Kumar; David Quigley; Li Tai Fang; Che-Chung Yeh; Zhidong Xu; David M Jablons; Liang You
Journal:  J Pathol       Date:  2014-06       Impact factor: 7.996

9.  Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma.

Authors:  Ting-Ting Liu; Huey-Ling You; Shao-Wen Weng; Yu-Ching Wei; Hock-Liew Eng; Wan-Ting Huang
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

10.  JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells.

Authors:  Bo Tang; Guangying Qi; Fang Tang; Shengguang Yuan; Zhenran Wang; Xingsi Liang; Bo Li; Shuiping Yu; Jie Liu; Qi Huang; Yangchao Wei; Run Zhai; Biao Lei; Hongping Yu; Xingyuan Jiao; Songqing He
Journal:  Oncotarget       Date:  2015-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.